More recently, it has been shown, in a preclinical study of patient-derived xenografts (PDXs) from CDK12HIGH and CDK12LOW human breast cancers, that CDK12 overexpression can predict response to metronomic methotrexate-based therapy. This evidence concerns the gene CDK12 and breast cancer.